![Long-Term Neuropsychological Outcomes from an Open-Label Phase I/IIa Trial of 2-Hydroxypropyl-β-Cyclodextrins (VTS-270) in Niemann-Pick Disease, Type C1 | SpringerLink Long-Term Neuropsychological Outcomes from an Open-Label Phase I/IIa Trial of 2-Hydroxypropyl-β-Cyclodextrins (VTS-270) in Niemann-Pick Disease, Type C1 | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40263-019-00642-2/MediaObjects/40263_2019_642_Fig2_HTML.png)
Long-Term Neuropsychological Outcomes from an Open-Label Phase I/IIa Trial of 2-Hydroxypropyl-β-Cyclodextrins (VTS-270) in Niemann-Pick Disease, Type C1 | SpringerLink
![Long-Term Neuropsychological Outcomes from an Open-Label Phase I/IIa Trial of 2-Hydroxypropyl-β-Cyclodextrins (VTS-270) in Niemann-Pick Disease, Type C1 | SpringerLink Long-Term Neuropsychological Outcomes from an Open-Label Phase I/IIa Trial of 2-Hydroxypropyl-β-Cyclodextrins (VTS-270) in Niemann-Pick Disease, Type C1 | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40263-019-00642-2/MediaObjects/40263_2019_642_Fig1_HTML.png)
Long-Term Neuropsychological Outcomes from an Open-Label Phase I/IIa Trial of 2-Hydroxypropyl-β-Cyclodextrins (VTS-270) in Niemann-Pick Disease, Type C1 | SpringerLink
Characterization of hydroxypropyl-beta-cyclodextrins used in the treatment of Niemann-Pick Disease type C1 | PLOS ONE
Computational Modeling Explains the Multi Sterol Ligand Specificity of the N-Terminal Domain of Niemann–Pick C1-Like 1 Protein | ACS Omega
Characterization of hydroxypropyl-beta-cyclodextrins used in the treatment of Niemann-Pick Disease type C1 | PLOS ONE
Chronic Cyclodextrin Treatment of Murine Niemann-Pick C Disease Ameliorates Neuronal Cholesterol and Glycosphingolipid Storage and Disease Progression | PLOS ONE
![Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1–2 trial - The Lancet Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1–2 trial - The Lancet](https://www.thelancet.com/cms/attachment/86568931-742b-4304-a289-4451d566366d/gr5_lrg.jpg)
Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1–2 trial - The Lancet
![β-Cyclodextrin-threaded Biocleavable Polyrotaxanes Ameliorate Impaired Autophagic Flux in Niemann-Pick Type C Disease* - Journal of Biological Chemistry β-Cyclodextrin-threaded Biocleavable Polyrotaxanes Ameliorate Impaired Autophagic Flux in Niemann-Pick Type C Disease* - Journal of Biological Chemistry](https://www.jbc.org/cms/asset/77158724-dd63-445e-8a3f-c6fefc0932ed/gr1.jpg)
β-Cyclodextrin-threaded Biocleavable Polyrotaxanes Ameliorate Impaired Autophagic Flux in Niemann-Pick Type C Disease* - Journal of Biological Chemistry
Chronic Cyclodextrin Treatment of Murine Niemann-Pick C Disease Ameliorates Neuronal Cholesterol and Glycosphingolipid Storage and Disease Progression | PLOS ONE
![Linear Cyclodextrin Polymer Prodrugs as Novel Therapeutics for Niemann-Pick Type C1 Disorder | Scientific Reports Linear Cyclodextrin Polymer Prodrugs as Novel Therapeutics for Niemann-Pick Type C1 Disorder | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-018-27926-9/MediaObjects/41598_2018_27926_Fig3_HTML.jpg)
Linear Cyclodextrin Polymer Prodrugs as Novel Therapeutics for Niemann-Pick Type C1 Disorder | Scientific Reports
![Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1–2 trial - The Lancet Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1–2 trial - The Lancet](https://www.thelancet.com/cms/attachment/77286517-ab06-4a0c-a7aa-ab06ee178484/gr4_lrg.jpg)
Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1–2 trial - The Lancet
![Pluronic based β-cyclodextrin polyrotaxanes for treatment of Niemann-Pick Type C disease | Scientific Reports Pluronic based β-cyclodextrin polyrotaxanes for treatment of Niemann-Pick Type C disease | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fsrep46737/MediaObjects/41598_2017_Article_BFsrep46737_Fig5_HTML.jpg)
Pluronic based β-cyclodextrin polyrotaxanes for treatment of Niemann-Pick Type C disease | Scientific Reports
![A therapy with miglustat, 2-hydroxypropyl-ß-cyclodextrin and allopregnanolone restores splenic cholesterol homeostasis in Niemann-pick disease type C1 | Lipids in Health and Disease | Full Text A therapy with miglustat, 2-hydroxypropyl-ß-cyclodextrin and allopregnanolone restores splenic cholesterol homeostasis in Niemann-pick disease type C1 | Lipids in Health and Disease | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12944-019-1088-2/MediaObjects/12944_2019_1088_Fig5_HTML.png)
A therapy with miglustat, 2-hydroxypropyl-ß-cyclodextrin and allopregnanolone restores splenic cholesterol homeostasis in Niemann-pick disease type C1 | Lipids in Health and Disease | Full Text
![A therapy with miglustat, 2-hydroxypropyl-ß-cyclodextrin and allopregnanolone restores splenic cholesterol homeostasis in Niemann-pick disease type C1 | Lipids in Health and Disease | Full Text A therapy with miglustat, 2-hydroxypropyl-ß-cyclodextrin and allopregnanolone restores splenic cholesterol homeostasis in Niemann-pick disease type C1 | Lipids in Health and Disease | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12944-019-1088-2/MediaObjects/12944_2019_1088_Fig4_HTML.png)
A therapy with miglustat, 2-hydroxypropyl-ß-cyclodextrin and allopregnanolone restores splenic cholesterol homeostasis in Niemann-pick disease type C1 | Lipids in Health and Disease | Full Text
Chronic Cyclodextrin Treatment of Murine Niemann-Pick C Disease Ameliorates Neuronal Cholesterol and Glycosphingolipid Storage and Disease Progression | PLOS ONE
![Cyclodextrin for Niemann-Pick Type C1 Disease | National Center for Advancing Translational Sciences Cyclodextrin for Niemann-Pick Type C1 Disease | National Center for Advancing Translational Sciences](https://ncats.nih.gov/files/trnd-cyclodextrin-npc.jpg)
Cyclodextrin for Niemann-Pick Type C1 Disease | National Center for Advancing Translational Sciences
![Linear Cyclodextrin Polymer Prodrugs as Novel Therapeutics for Niemann-Pick Type C1 Disorder | Scientific Reports Linear Cyclodextrin Polymer Prodrugs as Novel Therapeutics for Niemann-Pick Type C1 Disorder | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-018-27926-9/MediaObjects/41598_2018_27926_Fig1_HTML.jpg)
Linear Cyclodextrin Polymer Prodrugs as Novel Therapeutics for Niemann-Pick Type C1 Disorder | Scientific Reports
![Polyrotaxane-based systemic delivery of β-cyclodextrins for potentiating therapeutic efficacy in a mouse model of Niemann-Pick type C disease - ScienceDirect Polyrotaxane-based systemic delivery of β-cyclodextrins for potentiating therapeutic efficacy in a mouse model of Niemann-Pick type C disease - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S016836591731012X-gr3.jpg)
Polyrotaxane-based systemic delivery of β-cyclodextrins for potentiating therapeutic efficacy in a mouse model of Niemann-Pick type C disease - ScienceDirect
![Polyrotaxane-based systemic delivery of β-cyclodextrins for potentiating therapeutic efficacy in a mouse model of Niemann-Pick type C disease - ScienceDirect Polyrotaxane-based systemic delivery of β-cyclodextrins for potentiating therapeutic efficacy in a mouse model of Niemann-Pick type C disease - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S016836591731012X-fx1.jpg)
Polyrotaxane-based systemic delivery of β-cyclodextrins for potentiating therapeutic efficacy in a mouse model of Niemann-Pick type C disease - ScienceDirect
![Long-Term Neuropsychological Outcomes from an Open-Label Phase I/IIa Trial of 2-Hydroxypropyl-β-Cyclodextrins (VTS-270) in Niemann-Pick Disease, Type C1 | SpringerLink Long-Term Neuropsychological Outcomes from an Open-Label Phase I/IIa Trial of 2-Hydroxypropyl-β-Cyclodextrins (VTS-270) in Niemann-Pick Disease, Type C1 | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40263-019-00642-2/MediaObjects/40263_2019_642_Fig3_HTML.png)